Journals / Turkish Thoracic Journal / 2021 / Cilt: 22 - Sayı: 3

Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia

Pages
199–204
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This research paper assessed theefficacy of high-dose nebulized IFN α 2b in severe COVID-19 pneumonia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The COVID-19 pandemic is progressing rapidly, sending the world into a great panic.
📊
Key Findings & Data:Healthcare professionals haveresponded by embarking on a concerted search for therapies to cure and prevent COVID-19.
💡
Conclusion & Impact:This research paper assessed theefficacy of high-dose nebulized IFN α 2b in severe COVID-19 pneumonia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The COVID-19 pandemic is progressing rapidly, sending the world into a great panic. Healthcare professionals haveresponded by embarking on a concerted search for therapies to cure and prevent COVID-19. Recently, interferon (IFN) has emerged as apotential therapy as it is associated with reducing lung inflammation and suppressing viral replication. This research paper assessed theefficacy of high-dose nebulized IFN α 2b in severe COVID-19 pneumonia.

🔖

Cite This Article

CHKHİS, A., ABDULRAZZAQ, N., MOKHTAR, S., JASMİ, A. A. (2021). Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia. Turkish Thoracic Journal, Cilt: 22 - Sayı: 3, 199–204. https://ajindex.com/articles/395167

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Guo YR, Cao QD, Hong ZS et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020
  2. 7(1):11. [CrossRef] 2. Astuti I, Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020
  3. 14(4):407-412. [CrossRef] 3. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020
  4. 55(3):105924. [CrossRef] 4. Cascella M., Rajnik M, Cuomo A et al. Features, evaluation, and treatment of coronavirus. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing
  5. 2020 5. Arıkan H, Karadoğan D, Tokgöz Akyıl F et al. COVID-19 treatment at a glance. Turk Thorac J. 2020
  6. 21(6):438-445. [CrossRef] 6. Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review [review]. J Intern Med. 2021
  7. 289(2):147-161. [CrossRef] 7. Nile SH., Nile A., Qiu J et al. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020
  8. [CrossRef] 8. Davidson S, Maini MK, Wack A, Maini.MK. Disease-promoting effects of Type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res. 2015
  9. 35(4):252-264. [CrossRef] 9. Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016
  10. [CrossRef] 10. Essaidi-Laziosi M, Geiser J, Huang S et al. Interferon-dependent and respiratory virus-specific interference in dual infections of airway epithelia. Sci Rep. 2020
  11. 10(1):10246. [CrossRef] 11. Zhou Q, Chen V, Shannon CP et al. Interferon-α2b treatment for COVID-19. Front Immunol. 2020
  12. [CrossRef] 12. Hussain S, Xie YJ, Li D et al. Current strategies against COVID19. Chin Med. 2020
  13. [CrossRef] 13. Charles PG, Wolfe R, Whitby M et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008
  14. 47(3):375-384. [CrossRef] 14. Sheshadri A, Shah DP, Godoy M et al. Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. PLOS ONE. 2018
  15. 13(5):e0197418. [CrossRef] 15. Geng Y, Wei Z, Qian H et al. Pathophysiological characteristics and therapeutic approaches for